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ABSTRACT 
In the recent years, focus on the development of oral controlled release drug delivery systems has increased. Oral ingestion has been the most convenient and 
commonly employed route of drug delivery. Indeed, for sustained-release systems, the oral route of administration has by far received the most attention with 
respect to research on physiological and drug constraints. Sustained release dosage forms are designed to release a drug at a predetermined rate by maintaining 
a constant drug level for a specific period of time with minimum side effects. Sustained release of drugs in gastrointestinal tract following oral administration 
is not affected by the absorption process. Here this article concentrates on preparations, factors influencing, design, formulation, and the evaluation of oral 
sustained release preparations. The principal goal of sustained release dosage forms is the improvement of drug therapy assessed by the relationship between 
advantages and disadvantages of the use of sustained release systems.   
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INTRODUCTION  
If one were to imagine the ideal drug delivery system, two 
prerequisites would be required. First, it would be a single 
dose for the duration of treatment, whether it be for days or 
weeks, as with infection, or for the lifetime of the patient, as 
in  hypertension  or  diabetes.  Second,  it  should  deliver  the 
active entity directly to the site of action, thereby minimizing 
or eliminating side effects. This may necessitate delivery to 
specific  receptors,  or  to  localization  to  cells  or  to  specific 
areas  of  the  body.In  the  past  decade  great  interest  got 
generated on replacing conventional administration of drugs 
by  novel  delivery  systems  which  would  release  effective 
quantities from a protected supply at a controlled rate over a 
long  period  of  time.  Ideally  a  drug  to  provide  desired 
therapeutic action should arrive rapidly at the site of action 
(receptor) in optimum concentration, remain there for desired 
time, spare other sites and get removed from the site. One of 
the interesting results of pharmaceutical research is the fact 
that absorption rate of a drug can be decreased by reducing its 
rate  of  release  from  the  dosage  form.  The  products  so 
formulated  are  designated  as  sustained  action,  sustained 
release, delayed action, prolonged action, depot, repository, 
retarded release and timed release medication
1,2. 
ORAL  ROUTE  AS  THE  MOST  CONVENIENT 
ROUTE
3,4,5 
Oral ingestion has been the most convenient and commonly 
employed  route  of  drug  delivery.  Indeed,  for  sustained-
release systems, the oral route of administration has by far 
received  the  most  attention  with  respect  to  research  on 
physiological  and  drug  constraints  as  well  as  design  and 
testing of products. This is because there is more flexibility in 
dosage form design for the oral route than there is for the 
parenteral route.The reason that the oral route achieved such 
popularity  may  be  in  part  attributed  to  its  ease  of 
administration as well as the traditional belief that by  oral 
administration the drug is well absorbed as the food stuffs 
that  are  ingested  daily.  In  fact,  the  development  of 
pharmaceutical product for oral delivery, irrespective of its 
physical  form  involves  varying  extent  of  optimization  of 
dosage form characteristics within the inherent constraints of 
GI physiology. Therefore the fundamental understanding of 
various  disciplines,  including  GI  physiology, 
pharmacokinetics,  pharmacodynamics  and  formulation 
design are  essential to  achieve  a  systemic  approach  to  the 
successful  development  of  an  oral  pharmaceutical  dosage 
form. The more sophisticated a delivery system, the greater is 
the complexity  of these  various disciplines involved in the 
design  and  optimization  of  the  system.  In  any  case,  the 
scientific framework required for the successful development 
of  an  oral  drug  delivery  system  consists  of  a  basic 
understanding of the following three aspects:  
1. Physicochemical, pharmacokinetic and pharmacodynamic 
characteristics of the drug.  
2.  The  anatomic  and  the  physiologic  characteristics  of  the 
GIT. 
3. Physicochemical characteristics and drug delivery mode of 
the dosage form to be designed. 
The  goal  in  designing  sustained  or  controlled  delivery 
system is to
4,5 
Over the past 30 years, as the  expense and complications 
involved in marketing new drug entities have increased, with 
concomitant  recognition  of  the  therapeutic  advantages  of  
novel  drug delivery,  greater attention has  been  focused  on 
development of sustained or controlled release drug delivery 
system.  There  are  several  reasons  for  the  attractiveness  of 
these dosage forms. It is generally recognized that for many 
disease  states,  a  substantial  number  of  therapeutically 
effective  compounds  already  exists.  The  effectiveness  of 
these drugs however is often limited by side effects or the 
necessity to administer the compound in a clinical setting. 
The  major  goal  set  in  designing  sustained  or  controlled 
delivery is to: 
·  Reduce the frequency of dosing. 
·  Increase effectiveness of the drug by localization at 
the site of action. 
·  Reducing the dose required. 
·  Providing the uniform drug delivery. 
In  the  past,  many  of  the  terms  used  to  refer  therapeutic 
systems of controlled and sustained release have been used in 
an  inconsistent  and  confusing  manner.  Sustained  release, 
sustained action, prolonged action, controlled release (drug 
release with zero order kinetics) and repository dosage forms Chugh Isha et al. IRJP 2012, 3 (5) 
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are  terms  used  to  identify  drug  delivery  systems  that  are 
designed  to  achieve  prolonged  therapeutic  effects  by 
continuously releasing medication over an extended period of 
time after administration of a single dose. 
MODIFIED-RELEASE  DELIVERY  SYSTEMS  MAY 
BE  DIVIDED  CONVENIENTLY  IN  TO  FOUR 
CATAGORIES
6 
·  Delayed release.  
·  Sustained release.  
·  Site-specific targeting.  
·  Receptor targeting.  
Sustained-release systems include any drug-delivery system 
that achieves slow release of drug over an extended period of 
time. If the systems can provide some control, whether this is 
of a temporal or spatial nature, or both, of drug release in the 
body,  or  in  other  words;  the  system  is  successful  at 
maintaining constant drug levels in the target tissue or cells, it 
is considered a controlled-release system. 
Sustained Release Preparation
7 
These preparations may provide an immediate dose required 
for the normal therapeutic response, followed by the gradual 
release  of  drug  in  amounts  sufficient  to  maintain  the 
therapeutic response for a specific extended period of time 
usually 8-12 hrs. The major advantage of this category is that, 
in  addition  to  the  convenience  of  reduced  frequency  of 
administration, it provides blood levels that are devoid of the 
peak  and  valley  effect  which  are  characteristics  of  the 
conventional intermittent dosage regimen. Sustained release 
dosage forms are designed to complement the pharmaceutical 
activity  of  the  medicament  in  order  to  achieve  better 
selectivity and longer duration of action. 
Controlled Release Preparations
8  
Although  this  term  has  been  interchanged  widely  with 
sustained  release  preparation  in  the  past,  recently  it  has 
become customary to restrict the latter term to formulations 
where the mechanism of prolonged action is dependent on 
one or more of the environmental factors in  the GI tract such 
as  pH,  enzymes  concentration,  gastric motility  etc.  On  the 
other hand, the term controlled release dosage form usually 
applies  to  preparations  that  are  designed  for  all  routes  of 
administration and where the mechanism of prolonged action 
is  inherent  and  determined  totally  by  the  delivery  system 
itself. Consequently, this category offers the current state of 
the art products where the drug release profile is controlled 
accurately,  following  zero  order  kinetics  and  often  can  be 
targeted to a special body site or a particular organ.  
Advantages of Sustained Release Products
8   
1. Decreased local and systemic side effects: 
·  Reduced gastrointestinal irritation. 
2. Better drug utilization: 
·  Minimum drug accumulation on chronic dosing. 
3. Improved efficiency in the treatment: 
·  More uniform blood concentration. 
·  Reduction  in  fluctuation  in  drug  level  and  hence  more 
uniform pharmacological response. 
4. Improved patient compliance: 
·  Less frequent dosing. 
·  Reduced night-time dosing. 
5. Economy 
·  Although the initial unit cost of sustained release products 
is  usually  greater  than  that  of  the  conventional  dosage 
form because of the special nature of these products, the 
average cost of treatment over an extended time period 
may be less.  
Disadvantages
8 
1. Dose dumping: 
·  Dose dumping may occur with faulty formulations. 
2. Need for additional patient education: 
·  Patients may need substantial additional information as to 
the proper use of sustained release products e.g. “Do not 
crush or chew the dosage unit. Tablet residue may appear 
in the stools”. In some instances, patients must be started 
on an immediate release product and then switched over 
to the sustained release products. 
3. Possible reduction in systemic availability: 
·  Reduced systemic availability has been shown for some 
sustained  release  formulations  of  Theophylline, 
Procainamide and Vitamin combinations. 
BIOLOGICAL  FACTORS  INFLUENCING  ORAL 
SUSTAINED-RELEASE DOSAGE FORM DESIGN
1  
1. Biological Half-life 
Drug molecules  with short half-life are excellent candidate 
for  sustained-release  formulation,  since  this  can  reduce 
dosing frequency. However, this is limited, in that drugs with 
very short half-lives may require excessive large amounts of 
drug  in  each  dosage  unit  to  maintain  sustained  effects, 
forcing the dosage form itself to become limitingly large. In 
general  drugs  with  half-lives  shorter  than  2  hr  such  as 
furosemide  or  levodopa  are  poor  candidates  for  sustained-
release preparations. 
2. Absorption 
The absorption rate constant is an apparent rate constant, and 
should, in actuality, be the release rate constant of the drug 
from  the  dosage  form.  Compounds  that  demonstrate  the 
absorption rate constant will probably be poor candidates for 
sustaining systems. If a drug is absorbed by active transport, 
or  transport  is  limited  to  a  specific  region  of  intestine, 
sustained-release  preparations  may  be  disadvantageous  to 
absorption. 
3. Metabolism 
Drugs that  are  significantly  metabolized  before  absorption, 
either  in  the  lumen  or  tissue  of  the  intestine,  can  show 
decreased  bioavailability  from  slower-releasing  dosage 
forms. Most intestinal wall enzyme systems are saturable. As 
the drug is released at a slower rate to these regions, less total 
drug is presented to the enzymatic process during a specific 
period, allowing more complete conversion of the drug to its 
metabolite.  
PHYSIOLOGICAL  FACTORS  INFLUENCING  ORAL 
SUSTAINED-RELEASE DOSAGE FORMS
1,2  
1. Dosage Size 
In  general,  single  dose  of  500-1000  mg  is  considered 
maximal for a conventional dosage form. This also holds true 
for sustained-release dosage forms. Another consideration is 
the  margin  of  safety  involved  in  administration  of  large 
amounts of drug with a narrow therapeutic range.  
2. Ionization, pKa, and Aqueous Solubility 
Most drugs are weak acids or bases.  Since the unchanged 
form  of  a  drug  preferentially  permeates  across  lipid 
membranes, it is important to note the relationship between 
the pKa of the compound and the absorptive environment. 
Delivery systems that are dependent on 
diffusionor  dissolution  will  likewise  be  dependent  on  the 
solubility of drug in the aqueous media. For dissolution or 
diffusion sustaining forms, much of the drug will arrive in the 
small intestine in solid form, meaning that the solubility of 
the drug may change several orders of magnitude during its 
release.  The  lower  limit  for  the  solubility  of  a  drug  to  be Chugh Isha et al. IRJP 2012, 3 (5) 
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formulated  in    a  release  system  has  been  reported  to  be 
0.1mg/ml.  
3. Partition Co-efficient 
Compounds  with  a  relative  high  partition  co-efficient  are 
predominantly lipid soluble and consequently, have very low 
aqueous solubility. Furthermore these compounds can usually 
persist in the body for long period, because they can localize 
in the lipid membranes of cells. 
4. Stability 
Orally administered drugs can be subjected to both acid-base 
hydrolysis  and  enzymatic  degradation.  For  drugs  that  are 
unstable in the stomach, systems that prolong delivery over 
the  entire  course  of  transit  in  the  GI  tract  are  beneficial. 
Compounds  that  are  unstable  in  the  intestine  may 
demonstrate  decreased  bioavailability  when  administered 
from a sustained dosage form. 
DESIGN  AND  FORMULATION  OF  ORAL 
SUATAINED  RELEASE  DRUG  DELIVERY 
SYSTEM
10,11,12   
The oral route of administration is the most preferred route 
due  to  flexibility  in  dosage  form,  design  and  patient 
compliance. But here one has to take into consideration, the 
various pH that the dosage form would encounter during its 
transit, the gastrointestinal motility, the enzyme system and 
its influence on the drug and the dosage form. The majority 
of  oral  sustained  release  systems  rely  on  dissolution, 
diffusion or a combination of both mechanisms, to generate 
slow  release  of  drug  to  the  gastrointestinal  milieu. 
Theoretically  and  desirably  a  sustained  release  delivery 
device, should release the drug by a zero-order process which 
would result in a blood level time profile similar to that after 
intravenous constant rate infusion (as shown in figure 1, 2 
and 3) .  
Sustained (zero-order) drug release has been attempted to 
be  achieved  with  various  classes  of  sustained  drug 
delivery system 
1. Diffusion sustained system.  
i) Reservoir type.  
ii) Matrix type  
2. Dissolution sustained system.  
i) Reservoir type.  
ii) Matrix type  
3. Methods using Ion-exchange.  
4. Methods using osmotic pressure.  
5. pH independent formulations.  
6. Altered density formulations. 
1. Diffusion Sustained System 
Basically  diffusion  process  shows  the  movement  of  drug 
molecules from a region of a higher concentration to one of 
lower concentration. The flux of the drug J (in amount / area -
time),  across  a  membrane  in  the  direction  of  decreasing 
concentration is given by Fick’s law.  
J= - D dc/dx.  
D = diffusion coefficient in area/ time  
dc/dx = change of concentration 'c' with distance 'x'  
In common form, when a water insoluble membrane encloses 
a core of drug, it must diffuse through the membrane.  
The drug release rate dm/ dt is given by 
dm/ dt= ADK∆ C/L  
Where;  
 A = Area.  
 K = Partition coefficient of drug between the membrane and 
drug core.  
 L= Diffusion path length (i.e. thickness of coat).  
∆c= Concentration difference across the membrane. 
i) Reservoir Type 
In the system, a water insoluble polymeric material encases a 
core  of  drug  (Figure  4.).  Drug  will  partition  into  the 
membrane  and  exchange  with  the  fluid  surrounding  the 
particle  or  tablet.  Additional  drug  will  enter  the  polymer, 
diffuse to the periphery and exchange with the surrounding 
media.  
Characterization 
Description:  Drug  core  surrounded  by  polymer  membrane 
which controls release rate.  
Advantages:  Zero  order  delivery  is  possible,  release  rates 
variable with polymer type.  
Disadvantages:  System  must  be  physically  removed  from 
implant  sites.  Difficult  to  deliver  high  molecular  weight 
compound, generally increased cost per dosage unit, potential 
toxicity if system fails.  
ii) Matrix Type 
A solid drug is dispersed in an insoluble matrix (Figure 5.) 
and the rate of release of drug is dependent on the rate of 
drug diffusion and not on the rate of solid dissolution.  
Higuchi has derived the appropriate equation for drug release 
for this system: 
Q = Dε/ T [2 A –εCs] Cst 
½  
Where; 
Q = Weight in gms of drug released per unit area of surface 
at time t.  
D = Diffusion coefficient of drug in the release medium.   
ε = Porosity of the matrix.  
Cs = Solubility of drug in release medium.  
T= Tortuosity of the matrix.  
A = Concentration of drug in the tablet, as gm/ ml.  
Characterization 
Description:  Homogenous  dispersion  of  solid  drug  in  a 
polymer mixture. 
Advantages:  Easier  to  produce  than  reservoir  or 
encapsulated  devices,  can  deliver  high  molecular  weight 
compounds.  
Disadvantages: Cannot provide zero order release, removal 
of remaining matrix is necessary for implanted system. 
A third possible diffusional mechanism is the system where a 
partially soluble membrane encloses a drug core. Dissolution 
of part of membrane allows for diffusion of the constrained  
drug through pores in the polymer coat.  
The release rate can be given by following equation 
Release rate = AD / L = [ C1- C2 ]  
Where;  
A = Area.  
D = Diffusion coefficient.  
C1 = Drug concentration in the core.  
C2 = Drug concentration in the surrounding medium.  
L = Diffusional path length. 
Thus  diffusion  sustained  products  are  based  on  two 
approaches the  first approach  entails placement of the drug 
in  an  insoluble  matrix  of  some  sort.  The  eluting  medium 
penetrates the matrix and drug diffuses out of the matrix to 
the  surrounding  pool  for  ultimate  absorption.  The  second 
approach involves enclosing the drug particle with a polymer 
coat. In this case the portion of the drug which has dissolved 
in  the  polymer  coat  diffuses  through  an  unstirred  film  of 
liquid into the surrounding fluid.  
2. Dissolution Sustained Systems 
A drug with a slow dissolution rate is inherently sustained 
and  for  those  drugs  with  high  water  solubility,  one  can 
decrease  dissolution  through  appropriate  salt  or  derivative 
formation. These systems are most commonly employed in Chugh Isha et al. IRJP 2012, 3 (5) 
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the production of enteric coated dosage forms. To protect the 
stomach from the effects of drugs such as Aspirin, a coating 
that  dissolves  in  natural  or  alkaline  media  is  used.  This 
inhibits release of drug from the device until it reaches the 
higher  pH  of  the  intestine.    In  most  cases,  enteric  coated 
dosage forms are not truly sustaining in nature, but serve as a 
useful function in directing release of the drug to a special 
site. The same approach can be employed for compounds that 
are  degraded  by  the  harsh  conditions  found  in  the  gastric 
region.  
i) Reservoir Type 
Drug  is  coated  with  a  given  thickness  coating,  which  is 
slowly dissolved in the contents of gastrointestinal tract. By 
alternating layers of drug with the rate controlling coats as 
shown in figure, a pulsed delivery can be achieved.  If the 
outer layer is quickly releasing bolus dose of the drug, initial 
levels of the drug in the body can be quickly established with 
pulsed intervals. Although this is not a true sustained release 
system, the biological effects can be similar. An alternative 
method is to administer the drug as group of beads that have 
coating of different thickness. This is shown in figure. Since 
the  beads  have  different  coating  thickness,  their  release 
occurs  in  a  progressive  manner.  Those  with  the  thinnest 
layers will provide the initial dose. The maintenance of drug 
levels at late times will be achieved from those with thicker 
coating.    This  is  the  principle  of  the  spansule  capsule.  
Cellulose nitrate phthalate was synthesized and used as an 
enteric coating agent for acetyl salicylic acid tablets. 
ii) Matrix Type 
The more common type of dissolution sustained dosage form 
as  shown  in  figure  5.  It  can  be  either a  drug  impregnated 
sphere or a drug impregnated tablet, which will be subjected 
to slow erosion.  
Two  types  of  dissolution  sustained  pulsed  delivery 
systems 
·  Single bead type device  with alternating drug and rate-
controlling layer.   
·  Beads  containing  drug  with  differing  thickness  of 
dissolving coats. 
Amongst sustained release formulations, hydrophilic matrix 
technology is the most widely used drug delivery system due 
to following advantages: 
o  Provide  desired  release  profiles  for  a  wide  therapeutic 
drug category, dose and solubility. 
o  Simple  and  cost  effective  manufacturing  using  existing 
tableting unit operation equipment. 
o  Robust formulation. 
o  Broad regulatory and patient acceptance. 
o  Ease of drug release modulation through level and choice 
of polymeric systems and function coatings. 
A  hydrophilic  matrix  tablet  consists  of  mixture  of  drug, 
polymer  and  excipients  (filler/diluent  as  well  as  other 
excipients) prepared by common tableting equipment. Drug 
release  is  controlled  by  hydrophilic  (water  swellable) 
polymer in the matrix. Formulators often choose from a range 
of  hydrophilic  polymers,  as  stand  alone  or  in  combination 
with different polymers for release rate control. Majority of 
commercially successful hydrophilic matrix tablets are based 
on  HPMC  (hydroxy  propyl  methyl  cellulose)  due  to  wide 
range of chemistries and viscosity ranges to modulate release 
profiles of different dose / solubility characteristics of active 
pharmaceutical ingredient. 
 
 
3. Methods Using lon Exchange 
It is based on the formation of drug resin complex formed 
when a ionic solution is kept in contact with ionic resins. The 
drug from these complex gets exchanged in gastrointestinal 
tract  and  released  with  excess  of  Na
+  and  Cl
-  present  in 
gastrointestinal tract. 
·  Anion Exchangers: Resin
+ - Drug 
-  + Cl
-  goes to Resin
+ 
-  Cl
-  +  Drug
-    
·  Cation Exchangers: Resin
- - Drug
+  + Na
+ goes to Resin
-
 - Na
+ + Drug
+   
These  systems  generally  utilize  resin  compounds  of  water 
insoluble  cross  linked  polymer.  They  contain  salt  forming 
functional group in repeating positions on the polymer chain. 
The rate of drug diffusion out of the resin is sustained by the 
area of diffusion, diffusional path length and rigidity of the 
resin which is function of the amount of cross linking agent 
used  to  prepare  resins.  The  release  rate  can  be  further 
sustained  by  coating  the  drug  resin  complex  by 
microencapsulation process. 
4. Methods Using Osmotic Pressure 
A  semi  permeable  membrane  is  placed  around  a  tablet, 
particle or drug solution that allows transport of water into 
the tablet with eventual pumping of drug solution out of the 
tablet through a small delivery aperture in tablet coating.   
Two types of osmotically sustained systems are 
·  Type A contains an osmotic core with drug.  
·  Type  B  contains  the  drug  in  flexible  bag  with  osmotic 
core surrounding.  
5. pH– Independent Formulations 
The gastrointestinal tract present some unusual features for 
the  oral  route  of  drug  administration  with  relatively  brief 
transit  time  through  the  gastrointestinal  tract,  which 
constraint  the  length  of  prolongation,  further  the  chemical 
environment throughout the length of gastrointestinal tract is 
constraint on dosage form design. Since most drugs are either 
weak acids or weak bases, the release from sustained release 
formulations is pH dependent. However, buffers such as salts 
of amino acids, citric acid, phthalic acid phosphoric acid or 
tartaric  acid  can  be  added  to  the  formulation,  to  help  to 
maintain  a  constant  pH  thereby  rendering  pH  independent 
drug  release.  A  buffered  sustained  release  formulation  is 
prepared by mixing a basic or acidic drug with one or more 
buffering agent, granulating with appropriate pharmaceutical 
excipients and coating with gastrointestinal fluid permeable 
film forming polymer. When gastrointestinal fluid permeates 
through the membrane, the buffering agents adjust the fluid 
inside to suitable constant pH thereby rendering a constant 
rate of drug release e.g. propoxyphene in a buffered sustained 
release  formulation,  which  significantly  increase 
reproducibility.  
6. Altered Density Formulations
 
It  is  reasonable  to  expect  that  unless  a  delivery  system 
remains in the vicinity of the absorption site until most, if not 
all  of  it  it  would  have  limited  utility.  To  this  end,  several 
approaches  have  been  developed  to  prolong  the  residence 
time of drug delivery system in the gastrointestinal tract.
 
High Density Approach 
In this approach the density of the pellets must exceed that of 
normal stomach content and should therefore be at least 1-
4gm/cm
3. 
Low Density Approach 
Globular shells which have an apparent density lower than 
that  of  gastric  fluid  can  be  used  as  a  carrier  of  drug  for 
sustained release purpose.  Chugh Isha et al. IRJP 2012, 3 (5) 
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Evaluation of sustained release formulation
9 
In-Vitro Data 
The data is generated in a well-designed reproducible in-vitro 
test such as dissolution test. The method should be sensitive 
enough  for  discriminating  any  change  in  formulation 
parameters.  
The key elements for dissolution are 
o  Reproducibility of the method.  
o  Proper choice of media.  
o  Maintenance of sink condition.  
o  Control of solution hydrodynamics. 
o  Selection of the most discriminating variables (media, pH, 
rotation speed etc.) as the basis for dissolution test and 
specification. 
In-Vivo Data 
 This data consists of the following:  
o  Pharmacokinetic profile of the test product and reference 
product.  
o  Bioavailability  data-either  comparable  to  the  reference 
dosage  form  with  same  labeling  indications  and  same 
effects  or  non-equivalent  to  the  reference  dosage  form 
with demonstration  of  safety  and  efficacy  and different 
labeling.  
o  Evidence of reproducible in-vivo performance. 
CONCLUSION 
Development  of  oral  sustained  release  oral  dosage  form 
which will prolong the drug release leading to minimize the 
peak  and  valley  effect  in  plasma  and  provide  patient 
convenience. The advantages of sustained-release tablets or 
capsules are that they can often be taken less frequently than 
instant  formulations  of  the  same  drug,  and  that  they  keep 
steadier  levels  of  the  drug  in  the  bloodstream.  By  several 
approaches the residence time of drug delivery system in the 
gastrointestinal  tract  can  be  prolonged.  Difference  between 
controlled release and sustain release or sustained release is 
that controlled release is perfectly zero order release that is, 
the drug releases with time irrespective of concentration.On 
the  other  hand,sustain  release  or  sustained  release  implies 
slow release of the drug over a time period.It may or may not 
be controlled release. 
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Figure 1. Plasma drug concentration-profiles for conventional tablet or capsule formulation, a sustained release formulation, and a zero order 
sustained release formulation. 
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Figure 2. Comparison of Conventional and Controlled Release Profiles 
 
 
Figure 3. Dosage Regime for Conventional and Controlled Release Systems. 
 
 
Figure 4. Schematic representation of diffusion sustained drug release: Reservoir system 
 
 
Figure 5.  Schematic representation of diffusion sustained drug release: Matrix system 